Literature DB >> 10795400

Opioid receptor antagonists.

H Schmidhammer1.   

Abstract

Mesh：

Substances：

Year:  1998        PMID： 10795400

Source DB:  PubMed          Journal:  Prog Med Chem        ISSN： 0079-6468


× No keyword cloud information.
  13 in total

Review 1.  Kappa opioid antagonists: past successes and future prospects.

Authors:  Matthew D Metcalf; Andrew Coop
Journal:  AAPS J       Date:  2005-10-27       Impact factor: 4.009

2.  14-O-Heterocyclic-substituted naltrexone derivatives as non-peptide mu opioid receptor selective antagonists: design, synthesis, and biological studies.

Authors:  Guo Li; Lindsey C K Aschenbach; Hengjun He; Dana E Selley; Yan Zhang
Journal:  Bioorg Med Chem Lett       Date:  2008-12-29       Impact factor: 2.823

3.  Characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives as novel leads to development of mu opioid receptor selective antagonists.

Authors:  Yunyun Yuan; Guo Li; Hengjun He; David L Stevens; Patrick Kozak; Krista L Scoggins; Pallabi Mitra; Phillip M Gerk; Dana E Selley; William L Dewey; Yan Zhang
Journal:  ACS Chem Neurosci       Date:  2011-05-06       Impact factor: 4.418

4.  Binding mode characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives via docking in opioid receptor crystal structures and site-directed mutagenesis studies: application of the 'message-address' concept in development of mu opioid receptor selective antagonists.

Authors:  Saheem A Zaidi; Christopher K Arnatt; Hengjun He; Dana E Selley; Philip D Mosier; Glen E Kellogg; Yan Zhang
Journal:  Bioorg Med Chem       Date:  2013-09-04       Impact factor: 3.641

5.  14-Alkoxy- and 14-acyloxypyridomorphinans: μ agonist/δ antagonist opioid analgesics with diminished tolerance and dependence side effects.

Authors:  Subramaniam Ananthan; Surendra K Saini; Christina M Dersch; Heng Xu; Nicholas McGlinchey; Denise Giuvelis; Edward J Bilsky; Richard B Rothman
Journal:  J Med Chem       Date:  2012-09-27       Impact factor: 7.446

6.  Design and synthesis of a bivalent ligand to explore the putative heterodimerization of the mu opioid receptor and the chemokine receptor CCR5.

Authors:  Yunyun Yuan; Christopher K Arnatt; Guo Li; Kendra M Haney; Derong Ding; Joanna C Jacob; Dana E Selley; Yan Zhang
Journal:  Org Biomol Chem       Date:  2012-02-22       Impact factor: 3.876

7.  7α-Methoxy-carbonyl-6,7,8,14-tetra-hydro-6,14-endo-ethenothebaine.

Authors:  Mustafa Odabaşoğlu; Serkan Yavuz; Ozgür Pamir; Yılmaz Yıldırır; Orhan Büyükgüngör
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2009-03-25

8.  A Bivalent Ligand Targeting the Putative Mu Opioid Receptor and Chemokine Receptor CCR5 Heterodimers: Binding Affinity versus Functional Activities.

Authors:  Yunyun Yuan; Christopher K Arnatt; Nazira El-Hage; Seth M Dever; Joanna C Jacob; Dana E Selley; Kurt F Hauser; Yan Zhang
Journal:  Medchemcomm       Date:  2013-05-01       Impact factor: 3.597

9.  Opioid receptor selectivity profile change via isosterism for 14-O-substituted naltrexone derivatives.

Authors:  Yan Zhang; Orgil Elbegdorj; Yunyun Yuan; Irina O Beletskaya; Dana E Selley
Journal:  Bioorg Med Chem Lett       Date:  2013-05-16       Impact factor: 2.823

10.  Design, synthesis, and biological evaluation of 6alpha- and 6beta-N-heterocyclic substituted naltrexamine derivatives as mu opioid receptor selective antagonists.

Authors:  Guo Li; Lindsey C Aschenbach; Jianyang Chen; Michael P Cassidy; David L Stevens; Bichoy H Gabra; Dana E Selley; William L Dewey; Richard B Westkaemper; Yan Zhang
Journal:  J Med Chem       Date:  2009-03-12       Impact factor: 7.446
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.